Northern Trust
KYMR icon

Northern Trust’s Kymera Therapeutics KYMR Stock Holding History

Northern Trust’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.2M Buy
494,439
+27,417
+6% +$2.17M 0.01% 1224
2025
Q4 		$36.3M Buy
467,022
+29,902
+7% +$2.02M ﹤0.01% 1306
2025
Q3 		$24.7M Buy
437,120
+27,767
+7% +$1.25M ﹤0.01% 1545
2025
Q2 		$17.9M Sell
409,353
-12,307
-3% -$424K ﹤0.01% 1711
2025
Q1 		$11.5M Sell
421,660
-16,173
-4% -$590K ﹤0.01% 1956
2024
Q4 		$17.6M Buy
437,833
+53,658
+14% +$2.42M ﹤0.01% 1777
2024
Q3 		$18.2M Buy
384,175
+16,034
+4% +$708K ﹤0.01% 1677
2024
Q2 		$11M Sell
368,141
-4,645
-1% -$161K ﹤0.01% 1938
2024
Q1 		$15M Buy
372,786
+14,207
+4% +$508K ﹤0.01% 1795
2023
Q4 		$9.13M Sell
358,579
-7,676
-2% -$137K ﹤0.01% 2134
2023
Q3 		$5.09M Buy
366,255
+11,327
+3% +$228K ﹤0.01% 2433
2023
Q2 		$8.16M Buy
354,928
+18,101
+5% +$519K ﹤0.01% 2210
2023
Q1 		$9.98M Sell
336,827
-4,614
-1% -$149K ﹤0.01% 2014
2022
Q4 		$8.52M Buy
341,441
+9,703
+3% +$259K ﹤0.01% 2117
2022
Q3 		$7.22M Sell
331,738
-1,640
-0.5% -$43.2K ﹤0.01% 2218
2022
Q2 		$6.56M Buy
333,378
+13,508
+4% +$316K ﹤0.01% 2330
2022
Q1 		$13.5M Sell
319,870
-19,030
-6% -$804K ﹤0.01% 1950
2021
Q4 		$21.5M Buy
338,900
+177
+0.1% +$10.3K ﹤0.01% 1712
2021
Q3 		$19.9M Buy
338,723
+79,208
+31% +$4.59M ﹤0.01% 1816
2021
Q2 		$12.6M Buy
259,515
+142,014
+121% +$6.17M ﹤0.01% 2218
2021
Q1 		$4.57M Sell
117,501
-4,425
-4% -$266K ﹤0.01% 2812
2020
Q4 		$7.56M Buy
+121,926
New +$5.95M ﹤0.01% 2431

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Northern Trust's KYMR Position: Q1 2026 in Review

Northern Trust increased its Kymera Therapeutics (KYMR) stake by 5.9% in Q1 2026, buying an estimated $2.17M and bringing the position to 494,439 shares worth $41.2M. The position accounts for 0.01% of the portfolio, ranked #1224.

Northern Trust first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Northern Trust held 494,439 shares of Kymera Therapeutics worth $41.2M as of Q1 2026.
  • Northern Trust bought 27,417 Kymera Therapeutics shares in Q1 2026, an estimated $2.17M.
  • Kymera Therapeutics made up 0.01% of Northern Trust's portfolio in Q1 2026, its #1224 holding.
  • Northern Trust first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.